百济神州：替雷利珠单抗联合化疗用于可切除的NSCLC的3期RATIONALE 315试验达到其MPR和EFS主要终点

中国地震台网正式测定：10月22日09时54分在尼泊尔（北纬27.81度，东经84.74度）发生5.0级地震，震源深度10千米。（中国地震台网）","multimedia":{"img_url":["https://n.sinaimg.cn/zhibo/300/w150h150/20231022/a200-4be0f1bb26778ba22dd4da0e8ac43daa.jpg"]},"commentid":"live:finance-152-3329905:0","compere_id":0,"creator":"mengfei11@staff.sina.com","mender":"mengfei11@staff.sina.com","create_time":"2023-10-22 10:18:06","update_time":"2023-10-22 10:18:33","is_need_check":"0","check_time":"1970-01-01 08:00:01","check_status":"1","check_user":"","is_delete":0,"top_value":0,"is_focus":0,"source_content_id":"0","anchor_image_url":"","anchor":"直播员","ext":"{"stocks":[],"needPush":false,"needAIPush":false,"needCMSLink":true,"needCalender":false,"needProvince":"0"}","old_live_cid":"0","tab":"","tag":[{"id":"8","name":"其他"},{"id":"102","name":"国际"}],"like_nums":0,"comment_list":{"list":[],"total":0,"thread_show":0,"qreply":0,"qreply_show":0,"show":0},"docurl":"","rich_text_nick_to_url":[],"rich_text_nick_to_routeUri":[],"compere_info":""},{"id":3329904,"zhibo_id":152,"type":0,"rich_text":"【百济神州：替雷利珠单抗联合化疗用于可切除的NSCLC的3期RATIONALE 315试验达到其MPR和EFS主要终点】10月22日，百济神州官微宣布，3期临床试验RATIONALE 315达到了其双重主要终点：盲态独立病理学审查（BIPR）评估的主要病理学缓解（MPR）和盲态独立中心审查（BICR）评估的无事件生存期（EFS）。与安慰剂联合化疗作为新辅助治疗，并在术后接受安慰剂治疗相比，可切除的II期或IIIA期非小细胞肺癌（NSCLC）患者在术前接受替雷利珠单抗联合化疗，并在术后接受替雷利珠单抗单药治疗显示出具有统计学显著性和临床意义的改善。在新辅助治疗后，与化疗单药相比，替雷利珠单抗联合化疗在关键次要终点病理学完全缓解（pCR）方面也显示出具有统计学显著性的改善。